Ultragenyx Pharmaceutical Current Cash

Ultragenyx Pharmaceutical (RARE) currently reports a current cash of $130M as of June 2026. That compares with $190M in the prior-year period — down 32.6% year over year. Use the charts on this page to explore Ultragenyx Pharmaceutical's current cash history and peer comparisons.

Ultragenyx Pharmaceutical's current cash decreased from $190M to $130M — a 32.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Ultragenyx Pharmaceutical reported $130M in current cash as of June 2026. That compares with $190M in the prior-year period — down 32.6% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $130M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Ultragenyx Pharmaceutical, and consider following RARE for alerts when major investors trade the stock.

Ultragenyx Pharmaceutical is classified in the Healthcare sector. On current cash, it currently shows $130M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RARE with unrelated industries.